Ovarian reserve as a measure of adjuvant chemotherapy benefit in hormone receptor positive (HR-positive), HER2-negative, node-positive breast cancer in SWOG S1007 (RxPONDER).
Ann OncolJul 24, 2026 (epub)
K Kalinsky, W E Barlow, H B Pathak et al.
✦ AI-curated · Sources linked
In 30 seconds
The phase III RxPONDER trial evaluated the role of ovarian reserve markers in predicting the benefit of chemotherapy in premenopausal women with HR-positive, HER2-negative breast cancer. Among 1556 participants, those with AMH ≥10 pg/ml showed a significant improvement in invasive disease-free survival (IDFS) with chemotherapy (HR 0.46, P adj = 0.00012), while those with AMH <10 pg/ml did not benefit.
Key findings
- AMH ≥10 pg/ml was associated with a significant chemotherapy benefit for IDFS (HR 0.46, P adj = 0.00012).
- 64% of women with AMH ≥10 pg/ml experienced superior IDFS with chemotherapy compared to endocrine therapy alone.
- Participants with AMH <10 pg/ml did not show a benefit from chemotherapy (HR 1.27, P adj = 0.47).
- Ultrasensitive INHB also predicted chemotherapy benefit.
Why it matters
Understanding ovarian reserve through AMH levels can help clinicians better select premenopausal patients who are likely to benefit from chemotherapy, potentially improving treatment outcomes and avoiding unnecessary toxicity.